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ScienceDirectSynthetic biology enables a new generation of microbial
engineering for the biotechnological production of
pharmaceuticals and other high-value chemicals. This review
presents an overview of recent advances in the field, describing
new computational and experimental tools for the discovery,
optimization and production of bioactive molecules, and
outlining progress towards the application of these tools to
pharmaceutical production systems.
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The synthetic biology revolution
Synthetic biology has seen rapid advances in the last
couple of years. Initially focusing on proof-of-concept
studies illustrating our ability of writing genetic code
on a large scale and demonstrating the usefulness of
introducing engineering concepts into biology, the field
is now quickly moving towards industrial applications [1–
7]. In particular, the engineering of microbial production
systems for high-value small molecules is seen to hold
great potential, aiming at compounds that range from
flavours and fragrances to clinically relevant pharmaceu-
ticals [8]. While just a few years ago, synthetic biology was
seen as an avant-garde concept, its ideas and methods
have now largely entered the mainstream of molecular
biology and genetic engineering, so much so that the
necessity for its ambitious engineering metaphors is al-
ready being debated [9,10]. In this review we provide a
concise overview of some of the early achievements in the
synthetic biology of pharmaceuticals and the advances inCurrent Opinion in Biotechnology 2015, 35:46–51 tools (molecular and computational) that are expected to
drive this field forward rapidly.
Synthetic biology for pharmaceuticals
Pharmaceuticals have inspired some of the earliest suc-
cess stories of synthetic biology for two main reasons: on
the one hand, small-molecule drugs in current use (from
aspirin to artemisinin) are very often derived from natural
products, so that a return to microbial production systems
is seen as relatively straight-forward. On the other hand,
many natural biosynthetic pathways show a surprising
level of built-in modularity at many levels, which can be
exploited by the engineering approaches of synthetic
biology [11,12]. This is particularly true for the large
group of bioactive natural products that are active as
antibiotics and related compounds: the evolutionary
requirements for rapid diversification and for robust
cross-species compatibility of pathways that are constant-
ly exchanged between host organisms have shaped large
modular assembly lines that can serve as starting points
for synthetic biology. Cummings et al. [13] and Poust
et al. [14] have recently reviewed the possibilities and
limitations of this approach with a particular focus on
polyketide synthases, and Kittleson et al. examine the
challenges of modular genetic engineering from a broader
systems biological perspective [15].
The synthetic biology of pharmaceuticals is further in-
spired by the recent avalanche of microbial genome and
metagenome sequences which revealed an unexpected
richness of unexplored biosynthetic capacities in almost
every genome analysed [16,17]. For example, the recently
published first comprehensive assessment of secondary
metabolite diversity across microbial kingdoms, based on
the computational analysis of more than 1100 complete
genome sequences, detected more than 30 000 putative
biosynthetic gene clusters (estimating a false-discovery
rate of 5%) [18]. These were broadly distributed across
the phylogenetic tree, with clusters of particular richness
in, for example, actinomycetes, Burkholderia and Pseudo-
monas, but ‘talented’ strains of high predicted biosynthet-
ic capacity being found in almost every larger bacterial
group. A targeted analysis of Actinobacteria, combining
genome mining and metabolomics, concluded that this
group alone encodes for hundreds of thousands of possi-
ble drug leads [19]. Under standard conditions, the
majority of this biosynthetic potential is silent or cryptic,
and synthetic biology is seen as a potential tool for
awakening and mining this rich source of potential drug
candidates on a large scale [17,20–24]. Additional geneticwww.sciencedirect.com
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and further diversity, with new or improved bioactivity
[25,26].
Tools for the synthetic biology of
pharmaceuticals
Synthetic biology, like all engineering disciplines, relies
on the availability of powerful standardized tools for all
steps along the design–build–test (and learn) cycle. Many
of the required tools, for example genome synthesis,
assembly and editing methods [27–29], are broadly ge-
neric. Others are specific to the field of small-molecule
synthetic biology. These begin with methods for the
comprehensive discovery and annotation of biosynthetic
building blocks in newly sequenced genomes [30], as
exemplified by the antiSMASH pipeline [31,32]. In
combination with advances in mass spectrometry-based
analytics these annotations can be used to link genome
information directly to bioactive compounds observed in
bacterial cultures: this has recently been demonstrated for
peptidic metabolites (both non-ribosomal peptides and
Ribosomally synthesized and posttranslationally modified
peptides, RIPPs), where incomplete and noisy sequence
information derived from mass spectrometry can be used
to successfully identify the gene clusters likely to produce
them, and even to determine the actual structure of the
end product [33,34].
Another exciting source of biosynthetic building blocks is
promised by recent advances in the de novo computa-
tional design of enzymes with activities that were previ-
ously unavailable in biologicals systems [35]. Enzyme
engineering approaches also benefit from the increasing
availability of genome sequences, which allow evolution-
guided manipulation of existing enzymes, for example,
for altered substrate specificity in molecular assembly
lines for polyketides or non-ribosomal peptides
[36,37]. For example, identification of the recombination
events underlying a major switch in substrate specificity
during evolution of a bacterial non-ribosomal peptide
synthase, allowed Cru¨semann et al. [36] to create enzyme
variants that accepted alternative substrates, based on the
inferred recombination points.
Analogous evolutionary strategies can also be applied at
the pathway level, as demonstrated by the recent rational
design of novel functional polyketide synthases by emu-
lating the natural evolutionary processes underlying the
diversification of this biosynthetic class [38]. By exam-
ining the shared evolutionary history of the polyketides
aureothin, spectinabilin and luteoreticulin, it was possible
to develop a rational strategy of recombination and do-
main exchanges that reprogramme the aureothin polyke-
tide biosynthetic pathway into a pathway that produced
luteoreticulin. Protein engineering can also be very useful
at the small scale, for instance creating enzymatic build-
ing blocks that are not affected by the end-productwww.sciencedirect.com inhibition that is usually seen in natural enzymes.
Schendzielorz et al. recently demonstrated the power of
this ‘mutein’ approach in a case study on amino acid
biosynthesis in Corynebacterium glutamicum, where high-
throughput removal of inhibition allowed a massive in-
crease in production titres [39].
Other approaches to diversifying the pool of available
chemical building blocks rely on a variety of experimental
approaches. Walker et al. used synthetic biology to devel-
op a library of new fluorinated building blocks for bio-
molecules [40]. Starting from the fluoroacetate pathway
of Streptomyces cattleya, the only known natural source of
fluorinated biomolecules, they engineered acetate-based
polyketide biosynthesis to incorporate the fluorinated
precursor, via synthesis of fluoromalonyl-CoA as a modi-
fied extender unit. As many other natural products, rang-
ing from isoprenoids to steroids and alkaloids, are also
acetate-derived, this strategy offers potentially a general
approach for expanding the chemical space around known
pharmaceuticals.
The production of small molecules, whether awakened
from genome information or optimized in a native or
heterologous host, requires not only expression of the core
biosynthetic pathway, but also sufficient supply of pre-
cursors and reduced competition from alternative reac-
tions. Computational modelling has been useful for this
purpose, and the specific challenges of modelling for
secondary metabolite production have recently been
reviewed [41]. The increasing availability of automated
model construction and curation tools further increases the
accessibility of the technology [42] and enables, for exam-
ple, the comprehensive computational survey of potential
production hosts for heterologous pathways [43].
Other computational tools allow the design of the actual
pharmaceutical production system. A particularly ambi-
tious recent example is the Retropath tool for the princi-
pled design of entire metabolic circuits [44], based on
constraining information about the metabolic capacities
of the envisaged host organism (chassis) and the scope of
available chemical reactions. In addition to the produc-
tion modules, the Retropath framework also allows ex-
ploration of the design space for biosensing and regulation
of the synthetic pathways, with the ultimate aim of
enabling the construction of smart therapeutics, which
integrate pharmaceutical synthesis and point-of-need de-
livery. Proof-of-concept examples of similar devices have
recently been introduced, including engineered Escher-
ichia coli that can sense and kill Pseudomonas aeruginosa
biofilms by eavesdropping on the target quorum sensing
signals and releasing antibiotic pyocin proteins in re-
sponse [45].
While much of the actual DNA-level building of engi-
neered systems for pharmaceutical production relies onCurrent Opinion in Biotechnology 2015, 35:46–51
48 Pharmaceutical biotechnologygeneric tools, it is especially reliant on emerging methods
for the large-scale assembly of libraries of biosynthetic
pathways, to explore chemical space around existing
bioactive compounds or to discover new activities based
on hybrids and module-shuffled assemblies of biosynthet-
ic building blocks from various sources. A focused review
of DNA assembly methods available for this particular
challenge has recently been provided by Cobb et al. [46].
Recent developments in the use of phage integrases for
the multiplexed pathway assembly offer another impor-
tant contribution to the toolbox of synthetic biology
especially for the engineering of biosynthetic libraries
[47].
Moreover, the development of universal transfer and
expression systems specifically for large biosynthetic
gene clusters shuttled between species facilitates the
exploration of bioactive molecules from a variety of
sources. For example, Loeschke et al. introduced a sys-
tems that combines conjugation-based DNA transfer,
randomized transposition-based integration into the host
genome, and T7 RNA polymerase-driven bidirectional
transcription for concerted gene expression [48]. Applica-
tions to pigmented secondary metabolites, zeaxanthin
and prodigiosin, demonstrated the utility of this system
in different bacterial species. A similar system, specifical-
ly for bioprospecting in filamentous fungi, was recently
presented by Unkles et al. [49].
The design–build–test cycle is closed by the debugging
of the engineered microbes, for example, by high-resolu-
tion metabolomics, which allows not only the quantitation
of product levels, but more importantly a global assess-
ment of metabolic bottlenecks and potentially deleteri-
ous side reactions [50–52]. The insights gained at this step
are then available to drive another iteration of the cycle,
improving the predictive models and informing the next
steps in pathway engineering.
Applications of synthetic biology for
pharmaceuticals
The first and most widely publicized application of syn-
thetic biology for the industrial production of an impor-
tant drug is the case of semi-synthetic artemisinin. This
antimalarial drug was originally obtained from plant
sources but can now be produced at large quantities in
heterologous hosts, including Saccharomyces cerevisiae [53].
The project leading to the commercially viable engi-
neered strains took almost ten years and established a
large number of basic concepts and technologies required
for the successful design of biosynthetic systems for
pharmaceutical compounds [54], ranging from optimiza-
tion of the chassis organism for precursor supply (in this
case, artemisinic acid, which proved to be unavailable in
sufficient amounts even in engineered strains of the
originally intended production host E. coli), to the impor-
tance of eliminating or reducing unwanted side reactionsCurrent Opinion in Biotechnology 2015, 35:46–51 (such as the production of reactive oxygen species, which
severely limited the viability of early artemisinic acid
producing yeast strains). The ability to pursue many
design routes in parallel allowed the exploration of addi-
tional useful concepts, for instance the use of engineered
protein scaffolds to optimize the relative activities of
enzymes along a designer production pathway [55], or
the importance of subtle balancing of enzyme activities
along a pathway for optimal production [56,57].
Synthetic biology for other pharmaceuticals can now
build on the experiences of the artemisinin project,
and consequently the last few years have seen rapid
developments in the field, not only for closely related
isoprenoids, such as taxol [58], farnesene [59] and many
others [58,60–62].
Jaitzig et al. demonstrated the possibility of heterologous
expression of the huge molecular assembly lines required
for pharmaceutically interesting natural products in the
most attractive production host, E. coli [63]. They
expressed the entire 654 kDa non-ribosomal peptide
synthase for valinomycin in soluble and active form,
creating a valuable system to produce analogues of the
drug by making full use of the genome engineering
methods available for E. coli.
Shao et al. applied the refactoring strategy of synthetic
biology for awakening a silent biosynthetic pathway [64]:
by removing all native regulatory control of the spect-
abilin cluster of Streptomyces orinoci and replacing it with a
system of constitutive and inducible heterologous pro-
moters in a plug-and-play scaffold, they achieved the
straight-forward production of the end product at detect-
able levels amenable for analysis and further optimiza-
tion.
Klein et al. harnessed the power of synthetic biology in
yeast, S. cerevisiae, to create an entire library of 74 novel
chemical compounds enriched for bioactive compounds
[65]. Using randomly assembled biosynthetic pathways
from a variety of natural sources [66] in combination with
an internal activity screen in the same cells used for the
production, they were able to target the discovery process
towards molecules with structural and biophysical prop-
erties that comply with traditional rules for drug-likeness.
Important advances have also been made in the establish-
ing of engineered host systems (chassis) that are opti-
mized for the production of pharmaceuticals and other
secondary metabolites. Komatsu et al. developed ge-
nome-minimized variants of the industrial microbe Strep-
tomyces avermitilis, which grow faster than the wild type,
lacked the principal endogenous biosynthetic gene clus-
ters that often result in precursor competition and analyt-
ical complexity, and successfully achieved substantial
heterologous expression of a large number of secondarywww.sciencedirect.com
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environmental Pseudomonas strains exhibiting favourable
metabolic and stress-tolerance properties as promising
new hosts for biotechnological applications, based on
the increasing ability of synthetic biology to engineer
such non-classical model organisms [68]. Given the in-
creasing ease of genome engineering in multicellular
organisms, for example, using the CRISPR-Cas system
and related technologies [69,70], even plants (and plant
cell cultures) are increasingly returning to the focus as
potential biotechnological production systems for phar-
maceutical compounds, given their versatile endogenous
metabolism [71,72].
Conclusions
The use of microbial production systems for pharmaceu-
ticals and other high-value chemicals is clearly entering a
new phase right now. The ambitious engineering aims of
synthetic biology are rapidly becoming a reality, based on
advances in our ability to edit genomes, identify and
optimize biosynthetic building blocks, rapidly create
libraries of pathways and novel compounds, and to debug
and improve the engineered systems. As has always been
the case for natural products research, diversity will
remain a key feature: synthetic biology is built on diver-
sity of computational tools, genome engineering meth-
ods, analytical and screening technologies, but it also
enables new diversity at the level of host organisms
and chassis, as well as biosynthetic modules and bioactive
end products. All of these come together within the
shared framework of the design–build–test cycle of syn-
thetic biology, which in the coming years will move many
of the examples indicated in this review from the proof-
of-concept stage to wide-spread application in the phar-
maceutical industry.
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